



PATENT  
ATTORNEY DOCKET NO. 50125/037001

#9/B

Certificate of Mailing: Date of Deposit: 3/22/02

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Colleen Coyne  
Printed Name of Person Mailing Correspondence

Colleen Coyne  
Signature of Person Mailing Correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ingrid Jochmus et al.

Art Unit: 1648

Serial No.: 09/980,064

Examiner: A. Salimi

Filed: November 29, 2001

Customer No.: 21559

Title: CYTOTOXIC T-CELL EPITOPES OF THE PAPILLOMAVIRUS L1-  
PROTEIN AND USE THEREOF IN DIAGNOSTICS AND THERAPY

Assistant Commissioner For Patents  
Washington, DC 20231

PRELIMINARY AMENDMENT

Prior to examination, kindly amend the above-referenced application as follows.

In the Specification:

Insert the attached sequence listing at the end of the application.

Replace the third full paragraph on page 5 with the following paragraph re-written  
in clean form:

B1  
A functionally active variant of AQIFNKPYW (SEQ ID NO: 1) or AGVDNRECI (SEQ ID NO: 2) means a T-cell epitope which, in a T-cell cytotoxicity assay system (see, for example, Examples 2-5 of the present invention), has a cytotoxicity which, compared to the cytotoxicity of AQIFNKPYW (SEQ ID NO: 1) or AGVDNRECI (SEQ ID NO: 2), corresponds to at least the sum of the average of the negative controls and three times the standard deviation, preferably of at least approx. 30%, in particular at least approx. 50% and particularly preferably of at least approx. 80%.

Replace the paragraph beginning on page 5 and ending on page 6 with the  
following paragraph re-written in clean form: